Treatment of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy in Cipto Mangunkusumo Hospital During Pandemic Era (March 2020 - March 2022) Oral Presentation - Observational Study - Resident
Article Sidebar
-
vitreous hemorrhage, proliferative diabetic retinopathy, treatment, outcome
Abstract
Introduction & Objectives
Proliferative diabetic retinopathy (PDR) is the most common etiology for vitreous hemorrhage (VH)
and can be sight-threatening. Current treatment modalities for VH in PDR included anti-VEGF
injection, panretinal photocoagulation (PRP) laser, and vitrectomy. We conducted study to evaluate
treatment modalities and outcomes of VH in PDR during the pandemic era.
Methods
A retrospective study of VH in PDR was conducted at Cipto Mangunkusumo Hospital, Indonesia,
from March 2020 to March 2022. Primary treatment was the therapy planned at the initial visit,
while secondary treatment was subsequent treatment after follow-ups. Good anatomical outcome
was defined as vitreous clearing at last follow-up, while functional outcome was visual acuity (VA)
improvement in LogMAR.
Results
This study included 83 patients (97 eyes), which is smaller than the previous study in our center
before the pandemic. Mean age was 54,28±8,57 years, with almost equal males and females. Initial
VA was LogMAR 2,48 (0,15 – 2,80). The most frequent treatment for VH in PDR was vitrectomy
(53,5%), followed by anti-VEGF injection, PRP laser, and observation. Glaucoma after vitrectomy was
the most common complication (5,2%). Vitreous clearing was achieved in 85,5% of cases, which was
significantly associated with vitrectomy surgery (p=0,013) and initial treatment time (p=0,023). The
VA improvement was LogMAR -0,48(-2,48–2,40) which was related to initial VA (p<0.05), yet there
was no significant association with treatment modality.
Conclusion
Vitrectomy is essential to achieve vitreous clearing in VH caused by PDR. Initial visual acuity, not
the type of treatment modality, is a significant factor in vision improvement.
Full text article
References
Rush RB, Velazquez JC, Rosales CR, Rush SW. Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial. Am J Ophthalmol. 2022;242:173–80.
El Annan J, Carvounis PE. Current Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. Int Ophthalmol Clin. 2014;54(2):141–53.
Ali RS, Victor AA, Djatikusumo A, Andayani G, Yudanta AR, Hutapea MM. Clinical Characteristics of Proliferative Diabetic Retinopathy (PDR) Patients with Vitreous Hemorrhage at Cipto Mangunkusumo Hospital. Int J Retina. 2023 Feb 28;6(1):17–17.
Brant AR, Pershing S, Hess O, Rooney D, Goldberg J, Tabin G, et al. The Impact of COVID-19 on Missed Ophthalmology Clinic Visits. Clin Ophthalmol. 2021;15:4645–57.
Ashrafzadeh S, Gundlach BS, Tsui I. The Impact of NonOphthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown. Clin Ophthalmol. 2021;15:3661–8.
Fitri MAR, Yudantha AR. Pars Plana Vitrectomy for Vitreous Hemorrhage in Ciptomangunkusumo Hospital: Evaluation on Clinical Characteristics and Surgical Outcomes in Cipto Mangunkusumo Hospital in 2018. IJRetina. 2021;4(2):99–105.
Tanoey J, Becher H. Diabetes prevalence and risk factors of early-onset adult diabetes: results from the Indonesian family life survey. Glob Health Action. 14(1):2001144.
Banerjee S, Denniston AKO, Gibson JM, Dodson PM. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? Eye Lond Engl. 2004;18(8):821–5.
Manandhar L, Thapa R, Poudyal G. Clinical profile and management of vitreous hemorrhage in tertiary eye care centre in Nepal. Nepal J Ophthalmol. 2020;12:99–105.
Zhang T, Zhang J, Sun X, Tian J, Shi W, Yuan G. Early vitrectomy for dense vitreous hemorrhage in adults with non-traumatic and non-diabetic retinopathy. J Int Med Res. 2017;45(6):2065–71.
Saxena S, Jalali S, Verma L, Pathengay A. Management of Vitreous Haemorrhage. Indian J Ophthalmol. 2003;51(2):189–96.
Kimoto K, Kubota T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol. 2011;2012:e852183.
Balakrishnan D, Bhavna J, Nayaka A, Rani PK, Mukundaprasad V, Jalali S. Role of Tamponade in Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage - PubMed. Epub. 2017;32(4):48891.
Constantin BD, Andrei B, Andreea M. Vitrectomy surgery of diabetic retinopathy complications. Romanian J Ophthalmol. 2016;60(1):31–6.
Liao M, Wang X, Yu J, Meng X, Liu Y, Dong X, et al. Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients. BMC Ophthalmol. 2020 Oct 19;20(1):416.
Kornmann HL, Gedde SJ. Glaucoma management after vitreoretinal surgeries. Curr Opin Ophthalmol. 2016;27(2):125–31.
Baget-Bernaldiz M, Romero-Aroca P, Mercado-Gonzalez J, Bautista-Perez A, Soler-Lluís N, Navarro-Gil R. Risk factors for recurrent vitreous haemorrhage in patients with proliferative diabetic retinopathy. Res Sq. 2019;1–21.
Apriyani VK, Ihsan G, Virgana R, Sovani I. Immediate Versus Delayed Vitrectomy for The Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. Ophthalmol Ina. 2022;48(2):38–44.
Metita M, Sovani I, Kartasasmita A, Iskandar E, Virgana R. Surgical Approach in Vitreous Hemorrhage. Int J Retina. 2017;1(1):12–6.
Lee SS, Chang DJ, Kwon JW, Min JW, Jo K, Yoo YS, et al. Prediction of Visual Outcomes After Diabetic Vitrectomy Using Clinical Factors From Common Data Warehouse. Transl Vis Sci Technol. 2022 Aug 25;11(8):25.
Authors
Copyright (c) 2023 TSANIA RACHMAH RAHAYU, Gitalisa Andayani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
